We describe a study in which we investigated the cytotoxic activities of thymusderived (T) lymphocytes and natural killer cells against Epstein-Barr virus (EBV) genome-carrying lymphoid cell lines. Purified subpopulations of lymphocytes from eight patients with infectious mononucleosis and six healthy normal EBVseropositive donors were tested. Enriched T-cells were obtained by passing purified whole blood lymphocyte preparations through human immunoglobulinanti-immunoglobulin-coated glass bead columns. The cytolytic activity of effector cells was determined by the ability of these cells to lyse human target cells that were internally labeled with 51Cr. These targets included cells from both EBV genome-carrying and EBV genome-negative lymphoid lines derived from malignant tumors, as well as from lymphocytes transformed in vitro by EBV, and were chosen to represent a wide spectrum of EBV-associated membrane antigens. We found that cytotoxic T-cells from patients with infectious mononucleosis showed no EBV-related specific cell killing per se, although a trend for increased killing of cell lines derived from spontaneous in vivo growing tumors, EBV genome carrying or not, was noted; however, this trend was not observed with cell lines derived from cord blood lymphocytes after EBV infection in vitro. In addition, our data suggest that natural killer cells may play an important role in controlling EBV infection in patients with infectious mononucleosis in the acute phase of the disease, particularly since T-cells (obtained after removal on immunoglobulinanti-immunoglobulin columns of natural killer cells presumably bearing Fc receptors) were less efficient killers than whole blood lymphocytes; furthermore, lysis by whole blood lymphocytes was also greatest against cell lines derived from malignant tumors (as opposed to in vitro EBV-transformed cord blood lymphoid lines), irrespective of whether these targets were EBV genome positive or negative.
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Epstein-Barr virus (EBV) is the etiological agent of infectious mononucleosis (IM), a selflimiting lymphoproliferative disease (12) , and can transform or immortalize human and simian lymphocytes in vitro. In addition, the EBV genome is regularly detectable in the cells of two types of neoplasia, African Burkitt's lymphoma (BL) and undifferentiated nasopharyngeal carcinoma (23 (1, 16, 33, 42, 45, 46) . This mechanism was suggested by in vitro studies in which EBVcarrying cell lines were used as target cells.
In this study, we investigated the activities of cytotoxic thymus-derived (T) lymphocytes (CTLs) and natural killer (NK) cells (35) (11) . An equal part of phosphate-buffered saline (50 ml) containing 4 mM EDTA (6) was added to each blood sample, and the mixture was applied in 25-ml portions to 15 ml of Ficoll-Hypaque (3); the tubes were then centrifuged at 400 x g for 20 min. The lymphocyte-enriched layer at the plasma-Ficoll interface was gently aspirated, and the cells were washed three times with RPMI 1640 medium (GIBCO Laboratories, Burlington, Ontario, Canada). One part of this preparation was kept as whole lymphocytes; these cells were referred to as WBL.
(ii) Purification of T-lymphocytes. Enriched T-lymphocytes were obtained after filtration of WBL through an anti-immunoglobulin-coated glass bead column, as described previously (48) . This technique was chosen because it depletes not only B-cells, by virtue of absorbing surface immunoglobulin-bearing cells, but also Fc receptor-bearing cells (unpublished data); this is because the immunosorbent matrix is reacted first with human immunoglobulins and then with a xenogeneic rabbit anti-immunoglobulin antiserum, thus forming complexes with CH domains that are readily available for passing Fc receptor-bearing cells (6) . Removal of these cells was important because they are considered to be the effectors involved in NK activity (47) and thus could mask specific T-cell killing (13, 14) . The effluent cells were referred to as enriched T-cells.
(iii) Target cells. Target cells of different origins were selected to represent a wide spectrum of EBV-associated membrane antigens. The 16 cell lines used are listed in Table 1 ; the origin, EBV genome status, and surface characteristics of each cell line are also summarized in Table 1 . The cells were grown in tissue culture medium (RPMI 1640 medium) containing 100 pug of streptomycin per ml, 100 IU of penicillin per ml, and 10% heat-inactivated fetal bovine serum. All cultures were fed twice weekly and were maintained in stationary flasks at 37°C in a humidified CO2 incubator. For all assays, the target cells were harvested at an identical time (16 h after feeding of the cultures).
Analysis of cell surface markers. Four different approaches were used to assess the purity of the enriched T-cells and to investigate the lymphoid cell surface characteristics of the cell lines.
(i) E-rosette testing. Effector cell preparations (WBL and enriched T-lymphocytes) were monitored for their contents of cells capable of forming rosettes with sheep erythrocytes, the so-called E-rosette-forming cells, a marker for T-cells (19) . The detailed technical parameters of the method used have been described elsewhere (34) . For all of our tests with anti-immunoglobulin column-passed cells, the purity of the T-cell preparations exceeded 90%.
(ii) EA-rosette testing. The Fc receptor-bearing cells (erythrocyte antibody rosette-forming cells [EA-RFC]) among the effector-lymphocyte and target cell line populations were assayed for their capacity to form rosettes with oxerythrocytes sensitized with a subhemagglutinating dose of immunoglobulin G antibodies (18 on November 6, 2017 by guest http://iai.asm.org/ Downloaded from protein, using only RPMI 1640 medium; incubation was for 20 min at 37°C. Only preparations with less than 1% EA-RFC were used for enriched T-cell preparations.
(iii) EAC-rosette testing. In all cell lines, receptors for the activated C3 component of complement were assayed by using as indicator cells (EAC) human blood group A erythrocytes that we sensitized with a subhemagglutinating dose of 19S allogenic antibodies and then reacted with fresh mouse serum from strain A/Wu Sn, which congenitally lacks the C5 component. EACrosette-forming cell testing was then performed essentially as described above for EA-RFC, using a ratio of lymphocytes to EAC of 1:75.
(iv) Detection of surface-immunoglobulin-bearing cells. Effector lymphoid cells and target cell line populations were tested for the presence of membranebound immunoglobulin that was detectable by immunofluorescence by using a fluoresceinated goat antihuman immunoglobulin reagent (Hyland Laboratories, Inc., Costa Mesa, Calif.). Details of the assay used have been described elsewhere (7, 8) . In the antiimmunoglobulin column-passed cell populations, the percentage of B-lymphocytes with immunoglobulin expressed on the cell surface did not exceed 0.5%.
Cytotoxicity assay. (i) 51Cr labeling of target cells.
Samples of the different target cell lines were washed three times in RPMI 1640 medium, and then 5 x 106 cells were placed in 5-ml plastic tubes (type 2054; Falcon Plastics, Oxnard, Calif.) and centrifuged at 140 x g for 5 min. A 100-,u portion of sodium chromate (specific activity, 1 mCi/ml; New England Nuclear Corp., Lachine, Quebec, Canada) in 900 pul of RPMI 1640 medium supplemented with the same amounts of antibiotics and fetal bovine serum FBS that were used for the tissue cultures was added to each tube, and the cells were allowed to react in the pellet form for 60 min at 37°C. Then the cells were washed four times in RPMI 1640 medium, counted, and adjusted to a concentration of 10' cells per ml.
(ii) -5Cr release assay. The actual parameters used to assess the cytotoxic activities of the lymphocytes from the different individuals tested have been described extensively by other workers (36 was the spontaneous release, and max was the maximal 5tCr incorporation. Results were expressed as arithmetic means ±1 standard deviation for each group (WBL, enriched T-effector cells, IM patients, and normal controls), and statistical analysis was performed by the Student t test. Within each cell line, a statistical analysis was performed on the following three parameters: (i) the effect of fractionation on lymphocytes from IM patients; (ii) the differential cytotoxicity levels between IM patients and normal controls for unfractionated WBL; and (iii) the differential cytotoxicity levels between IM patients and normal controls for enriched T-cells. Finally, a chi-square analysis was done to compare the overall relative cytotoxicity levels of IM blood and normal blood with respect to combined data obtained from a group of cell lines with similar characteristics (i.e., EBV genomecarrying BL cell lines or EBV-infected cord bloodderived lymphoid cell lines).
RESULTS
Cytotoxicity of blood lymphocytes against EBV genome-carrying lines versus K-562 cells. In the first part of this study, we investigated whether WBL or enriched T-cells from IM patients or both differed from the corresponding lymphocyte populations from normal individuals in their capacity to kill the following three different types of target cells (Table 1) : (i) K-562; (ii) Raji, B35M, and P3HR-1; and (iii) B85.
As Fig. 1 When cells of the spontaneously in vitroderived cell line B-85 were used as targets for both IM and normal lymphocytes, no statistical difference in the cytotoxic activity of IM lymphocytes was observed, whether they were depleted of EA-RFC or not.
Cytotoxicity of blood lymphocytes against in vitro EBV-converted lymphoma-derived cell lines. When cell line BJA-B and its in vitro EBVconverted sublines were used as target cells in parallel with K-562 cells for assessing NK activity, the same cytotoxicity pattern described above ( Fig. 1) was observed with K-562 cells, confirming that EA-RFC depletion and, consequently, NK annihilation were achieved very effectively (Fig. 2) . When these lines were tested as target cells for lymphocytes from IM patients and controls, two different cytotoxicity patterns were observed. In the first pattern the cytotoxic activity of IM WBL was slightly greater than the cytotoxic activities of control lymphocytes for BJA-B, BJA-B-95-8, and BJA-A5 cells; the removal of EA-RFC did not affect to any significant extent the capacity of enriched T-cells from IM patients to kill any of these targets (Fig. 2) . Depletion of Fc receptor-bearing cells from the lymphocytes of normal individuals also did not decrease the cytotoxic activity of the lymphocytes; in fact, it enhanced their cytolytic capacity. In the second pattern, P3HR-1-converted BJA-B sublines BJA-P3HR-1 and BJA-B1 were killed to a greater extent by lymphocytes from IM patients than by lymphocytes from a healthy control, although the difference was not statistically significant; EA-RFC depletion significantly diminished the cytotoxic activities of both types of lymphocytes but did not totally abolish the activities compared with K-562 cells. This finding was essentially identical to what we observed with the three BL-derived cell lines described above (Fig. 1) . Thus, especially when EBV genome-negative cell line BJA-B was compared with its EBV-converted sublines as sources of target cells, no EBV-specific recognition characteristics by T-cells could be attributed to the lymphocytes from IM patients.
Cytotoxicity of peripheral blood lymphocytes against in vitro EBV-transformed cord blood lymphoid cell lines. In the experiments described above, only BL cell lines and one lymphoid cell line derived in vitro from an EBV-seropositive leukemic individual were used as target cells. For the vast majority of these cell lines, IMderived lymphocytes were more efficient killers than cells obtained from normal controls. The specificity for EBV-related membrane components could not be established despite the use of highly purified T-cell subpopulations deprived of NK cells. To investigate further the reactivity of IM WBL toward EBV-infected cells, we used a battery of in vitro-derived lymphoid cell lines obtained after in vitro EBV infection of cord blood cells from four different newborn donors. These donors were not infected in utero with EBV (8) ; despite this, the resulting cell lines behaved in vitro and expressed EBV-induced antigens like the adult-derived cell lines (28) .
As Fig. 3 shows, the cytotoxic potentials of lymphocytes from both IM and normal individuals toward cord blood lymphoid cell lines were relatively small compared with the cytotoxic potential observed with K-562 cells. Overall, whole blood effector cells behaved similarly whether they were obtained from IM patients or from normal subjects. However, as a group the enriched T-cells from all normal individuals were more efficient in killing lymphoid cell lines than the purified T-cells from IM patients were. variable, depending upon the EBV-infected cell line used. In some cases, this reactivity is even surpassed by that observed with lymphocytes from healthy individuals (Fig. 3) . Furthermore, cytotoxicity of lymphocytes from IM patients is also present at a very significant level with an EBV genome-negative BL cell line (BJA-B) (Fig. 2) and with an EBV-negative cell line (K-562). With regard to the BJA-B target cells, as well as to the EBV-infected cord blood cell lines, enrichment of T-cells leads to a relative increase in the killing activity of lymphocytes from normal donors ( Fig. 2 and 3 (2, 33a) . It is also noteworthy that in the murine system it has been shown that NK and antibody-dependent cell-mediated cytotoxicity activities against cytomegalo-virus-infected targets are detected significantly earlier than specific CTL-mediated cytotoxicity (38) . Thus, at present we cannot rule out the possibility that a similar pattern may occur in human subjects undergoing viral infections.
The relatively poor cytotoxicities exhibited by lymphocytes from both IM patients and normal donors toward in vitro EBV-transformed cell lines are in accordance with the results obtained recently by Jondal et al. (20) . The difference in susceptibility to lysis between cord blood-derived lines and BL-derived target cells may be due to the many differences (mainly in the cell surface characteristics) between these B-cell lines (32) . On the other hand, it is also probable that cord blood-derived lines may be killed by a mechanism(s) other than CTL-mediated cytotoxicity. One reason for the insensitivity of cord blood-derived lines to CTL-mediated lysis could relate to the age of these cell lines, as it has recently been reported by Seeley et al. (43) that younger cultures (<12 months old) may be more resistent to CTL lysis than older lines. Interestingly, all of the cord blood-derived lines used in the present study (Table 1) were only 2 to 6 months old. It is also noteworthy that, in contrast to our results, Seeley et al. (43) found that young target cells were sensitive to CTL from IM patients; the reasons for these discrepancies are not known at present.
In conclusion, the evidence presented above clearly indicates that the T-lymphocytes from patients in the acute phase of IM are not specifically directed against EBV-infected cells per se. Thus, our data are in agreement with the very recent suggestions by other investigators that it is at present difficult to detect an EBV-specific component in the action of T-cells in the acute phase of IM exerted on B-cells (21) and that most, if not all, of the cytotoxicity from IM effectors might be mediated by a type of activated NK cell which is not truly EBV specific (41) .
